GSK plc

Chart & Performance

D1W1MN

P/E

10.94

P/S

1.78

EPS

1.21

Div Yield, %

3.33%

Shrs. gr., 5y

0.67%

Rev. gr., 5y

-0.32%

Revenues

30.33b

+3.42%

Net income

4.93b

-67.05%

CFO

6.77b

-8.58%

Dividend

Aug 15, 20240.192 USD/sh

Earnings

Feb 05, 2025

Profile

GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, HIV, immuno-inflammation, oncology, anti-viral, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterial, and dermatology. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories. The company offers its consumer healthcare products in the form of nasal sprays, tablets, syrups, lozenges, gum and trans-dermal patches, caplets, infant syrup drops, liquid filled suspension, wipes, gels, effervescents, toothpastes, toothbrushes, mouthwashes, denture adhesives and cleansers, topical creams and non-medicated patches, lip balm, gummies, and soft chews. It has collaboration agreements with 23andMe; Lyell Immunopharma, Inc.; Novartis; Sanofi SA; Surface Oncology; Progentec Diagnostics, Inc.; Alector, Inc.; and CureVac AG., as well as strategic partnership with IDEAYA Biosciences, Inc. and Vir Biotechnology, Inc. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.

URL

https://www.gsk.com/

IPO date

May 22, 1972

Employees

69,400

Domiciled in

Incorporated in

Valuation

Order:

Title GBP in thousands, except ratios and share amounts	FY	FY	FY	FY	FY	FY	FY	FY	FY	FY
Title GBP in thousands, except ratios and share amounts	2023‑12	2022‑12	2021‑12	2020‑12	2019‑12	2018‑12	2017‑12	2016‑12	2015‑12	2014‑12
Income
Revenues	30,328,000 3.42%	29,324,000 -14.04%	34,114,000 0.04%
Cost of revenue	24,173,000	23,414,000	27,856,000
Unusual Expense (Income)
NOPBT	6,155,000	5,910,000	6,258,000
NOPBT Margin	20.29%	20.15%	18.34%
Operating Taxes	756,000	707,000	346,000
Tax Rate	12.28%	11.96%	5.53%
NOPAT	5,399,000	5,203,000	5,912,000
Net income	4,928,000 -67.05%	14,956,000 241.07%	4,385,000 -23.73%
Dividends	(2,247,000)	(3,467,000)	(3,999,000)
Dividend yield	3.77%	5.91%	7.60%
Proceeds from repurchase of equity	10,000	(1,546,000)	(1,622,000)
BB yield	-0.02%	2.63%	3.08%
Debt
Debt current	2,813,000	3,952,000	3,601,000
Long-term debt	16,412,000	18,043,000	21,587,000
Deferred revenue		83,000	85,000
Other long-term liabilities	9,937,000	9,833,000	9,878,000
Net debt	13,274,000	16,731,000	18,700,000
Cash flow
Cash from operating activities	6,768,000	7,403,000	7,952,000
CAPEX	(1,314,000)	(2,258,000)	(2,931,000)
Cash from investing activities	(1,595,000)	(8,772,000)	(1,777,000)
Cash from financing activities	(5,641,000)	823,000	(7,589,000)
FCF	5,062,000	4,860,000	7,641,000
Balance
Cash	5,182,000	7,877,000	4,335,000
Long term investments	769,000	(2,613,000)	2,153,000
Excess cash	4,434,600	3,797,800	4,782,300
Stockholders' equity	8,035,000	5,208,000	16,220,000
Invested Capital	36,315,400	36,730,200	50,206,700
ROIC	14.78%	11.97%	11.82%
ROCE	15.10%	14.48%	10.69%
EV
Common stock shares outstanding	4,111,000	4,084,000	3,241,600
Price	14.50 0.88%	14.38 -11.41%	16.23 19.72%
Market cap	59,617,722 1.54%	58,711,584 11.61%	52,603,712 -3.71%
EV	72,339,722	74,988,584	77,590,712
EBITDA	8,449,000	8,208,000	8,782,000
EV/EBITDA	8.56	9.14	8.84
Interest	775,000	879,000	784,000
Interest/NOPBT	12.59%	14.87%	12.53%